Posted by admin on Aug 5th, 2022
NuVasive (NASDAQ:NUVA – Get Rating) and H-CYTE (OTCMKTS:HCYTD – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
This table compares NuVasive and H-CYTE’s net margins, return on equity and return on assets.
This table compares NuVasive and H-CYTE’s gross revenue, earnings per share (EPS) and valuation.
H-CYTE has lower revenue, but higher earnings than NuVasive.
This is a summary of recent ratings for NuVasive and H-CYTE, as reported by MarketBeat.com.
NuVasive currently has a consensus price target of $62.60, indicating a potential upside of 22.77%. Given NuVasive’s higher probable upside, research analysts clearly believe NuVasive is more favorable than H-CYTE.
NuVasive has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
NuVasive beats H-CYTE on 8 of the 9 factors compared between the two stocks.
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.
Head-To-Head Analysis: Bain Capital Specialty Finance (NYSE:BCSF) versus E.Merge Technology Acquisition (NASDAQ:ETAC)
Baxter International (NYSE:BAX) Hits New 52-Week Low Following Analyst Downgrade